We are international
Donate
TEXT SIZE   
back

Myeloma Minute
June 13, 2013
06.13.13
June 13, 2013
Share the Minute Facebook Tweet!
Clinical Trials
Donate to the IMF
 



Watch this week's episode
of #AskDr.Durie, the IMF's weekly web series


Upcoming Events




Thursday, June 20, 2013
4 pm PT/ 7 pm ET
Living Well Teleconference:
The Advantages of Good Nutrition

Angela Hummel MS, RD, CSO, LDN


Saturday, June 22, 2013
Cincinnati Regional Community Workshop
Cincinnati, Ohio



Saturday, July 13, 2013
Spokane Regional Community Workshop
Spokane, Washington


 

Shop the IMF Mall & Support the IMF

Myeloma Minute: Special Edition - the IMF in Stockholm!

This special edition of the Myeloma Minute comes to you from Stockholm, Sweden, where the International Myeloma Foundation team has been reaching across borders this week to collaborate on myeloma research and patient advocacy on the eve of the 18th Annual Congress of the European Hematology Association (which begins here on Friday, June 14).
x
Collaborating Across Borders to Advance Myeloma Research and Advocacy




More than seventy of the world's leading myeloma experts gathered in Stockholm this week for the 4th Annual International Myeloma Working Group (IMWG) Summit: "Key Questions 2013." Organized by the IMF and led by IMF Chairman Brian GM Durie, MD, the Summit brings together researchers from around the world each year to grapple with subjects of vital concern to the myeloma community. "This collaborative effort has made a profound difference in bringing forward breakthroughs in treatment options and diagnostic systems that prolong lives," said Dr. Durie.

On Tuesday and Wednesday mornings this week, presentations of myeloma data prompted energetic discussions between audience members and panelists in the main auditorium. The need to arrive at a consensus for a definition of "early myeloma" was a popular subject, as was the question of how early to begin myeloma treatment, a topic which was returned to repeatedly throughout the Summit. In the collegial spirit that characterizes the IMWG Summit, participants divided up into small working groups and, over lunch Tuesday, shared ideas about "Frontline Therapy," "Maintenance Therapy," "Transplant," and "CR Assessment and MRD."

A new feature of the Summit this year was the participation by representatives of myeloma patient organizations from Latin America, Canada and the U.S., who brought their personal perspectives to the discussions. As IMF President and Co-founder Susie Novis told attendees, "It's so important to include patient groups here. Nothing can make patients do better than when they know a cure is somewhere in the future."
x
The Robert A. Kyle Lifetime Achievement Award Bestowed in a Historic Swedish Setting
The Hall of Mirrors at Stockholm's Grand Hotel was the historic setting for the IMF's 11th Annual Robert A. Kyle Lifetime Achievement Award held on Tuesday evening and honoring Prof. Gösta Gahrton of the Karolinska Institutet. The ballroom was where the first Nobel Prize ceremony and banquet took place beginning in 1901 and continued until the ceremony was moved to larger quarters in 1926. After listening to testimony about his outstanding work in the field of multiple myeloma, Prof. Gahrton took the stage and joked, "At times like this, maybe you have to take all this with a grain of salt." Then he graciously thanked everyone with whom he had collaborated, as well as his wife, Astrid, their children and grandchildren, and "the whole myeloma community!"

x
Missed the Live Webcast of 'Making Sense of Treatment'? Watch an Archive of the IMWG's Popular Conference Series Debate
If you missed the live webcast this week of "Making Sense of Treatment," the International Myeloma Working Group (IMWG) Conference Series broadcast from the 2013 IMWG Summit in Stockholm, Sweden, you can watch an archived version. Myeloma experts Dr. Brian GM Durie, Chairman and Co-founder of the IMF, Dr. Joseph Mikhael, Dr. Ola Landgren, and Dr. Antonio Palumbo tackle the key questions facing myeloma doctors and their patients, and reveal what, in their opinions, are the hottest topics in the myeloma field today.WATCH HERE

x
Watch Archive of IMF International Journalists' Workshop from Stockholm
Journalists from Austria, France, Germany, Greece, Italy, Mexico, Netherlands, Portugal, Russia, Spain, Sweden, Switzerland and the UK came to the IMF International Journalists' Workshop in Stockholm Thursday evening to report on the latest developments in myeloma research. Briefing the international media were Dr. Brian GM Durie, IMF Chairman and Co-founder; Dr. Xavier Leleu, Hôpital Claude Huriez, CHRU, Lille, France; and Dr. Paul Richardson, Dana-Farber Cancer Institute, Boston. WATCH THE ARCHIVED WEBCAST HERE
 

Join Our Mailing List

 
12650 Riverside Drive, Suite 206 | North Hollywood, CA 91607-3421
IMF Hotline: 800-452-2873 or 818-487-7455
Privacy Policy | Unsubscribe 
www.myeloma.org

 related videos
 related articles
#AskDrDurie: My Mai...
#AskDrDurie: Can Mye...
10 PASSI PER CURA MI...
10 Steps to Better C...
10 Steps to Happy Ho...
2011 IMF Holiday Gif...
New Study: The Searc...
Comprender El Tratam...
...
ABOUT BSRI™
ABOUT BSRI®
Advocacy Update - Ap...
Advocacy Update - Ma...
Advocacy Update - Oc...
Advocacy Update - Se...
Advocacy Update: The...
As the Bill Turns......
ASCO 2012: Dr. Pasho...
ASCO 2013: Dr. Jakub...
ASCO 2013: Dr. Lonia...
ASCO 2013: Dr. Pande...
ASCO 2013: Dr. Usman...
ASCO 2013: Dr. Weise...
ASH 2012: A PREVIEW
ASH 2013: Dr. Ken An...
Audio Recording of C...
August 2013 Advocate...
Breaking News: Pomal...
FDA Recognition of E...
Health Reform and Yo...
IMF 6th Annual Comed...
IMF Board Member Edi...
IMF Nurse Leadership...
IMF Responds to Prop...
It is Officially Mye...
jc test
Live from ASH 2012: ...
Live! The Boca Raton...
Living Well with Mye...
Myelom Merkur - Früh...
MYELOMA AWARENESS MO...
Myeloma Canada Annou...
Myeloma Minute Apri...
Myeloma Minute Apri...
Myeloma Minute Apri...
Myeloma Minute Febr...
Myeloma Minute Janu...
Myeloma Minute July...
Myeloma Minute June...
Myeloma Minute Marc...
Myeloma Minute May ...
Myeloma Minute Nove...
Myeloma Minute Octo...
Myeloma Minute Octo...
Myeloma MinuteMay 24...
Myeloma Today Spring...
New! Free Teleconfer...
Patienten Handbuch
Pomalidomide + carfi...
Should Myeloma Patie...
Special Myeloma Minu...
STEP 7: CONSOLIDATIO...
STEP 8: KEEPING TRAC...
Stillwater, Minn., M...
Teleconference: Myel...
The Emerging Role of...
The Hope Society
THE IMF AT ASH 2012
The IMF Spearheads N...
The Importance of Cl...
The International My...
The International My...
The International My...
View the IMF’s Multi...
Webcast from the 201...
Клиническое значение...

ASCO 2012: Dr. Pashos - Race- and health-related quality of life among patients newly diagnosed with multiple myeloma
ASCO 2013: Dr. Jakubowiak - Treatment outcome with the combination of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) for newly diagnosed multiple myeloma (NDMM) after extended follow-up.
ASCO 2013: Dr. Lonial - Phase (Ph) I/II study of elotuzumab (Elo) plus lenalidomide/dexamethasone (Len/dex) in relapsed/refractory multiple myeloma (RR MM): Updated Ph II results and Ph I/II long-term safety.
ASCO 2013: Dr. Pandey - Beneficial effect of complete response and type of therapy in multiple myeloma.
ASCO 2013: Dr. Usmani - Retrospective analysis of cardiovascular (CV) events following compassionate use of carfilzomib (CFZ) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM).
ASCO 2013: Dr. Weisel - MM-003: A phase III, multicenter, randomized, open-label study of pomalidomide (POM) plus low-dose dexamethasone (LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM).
jc test
#AskDrDurie: My Maintenance was Stopped Because the Side Effects were Too Bad. How Common is That?
#AskDrDurie: Can Myeloma Run In The Family?
10 PASSI PER CURA MIGLIORE®
10 Steps to Better Care®
10 Steps to Stress Control – From Fear to Hope
10 Steps to Happy Holidays
2011 IMF Holiday Gift Boutique

New Study: The Search for Criteria to Diagnose Active Myeloma at an Early Stage

Comprender El Tratamiento con Dosis Altas con Rescate de Células Madre



Third in the popular series of debates that debuted in Amsterdam in 2012.

Conference aired at 1:00 pm CEST/7:00 am Eastern/4:00 am Pacific

ABOUT BSRI™
ABOUT BSRI®
Advocacy Update - April 2013
Advocacy Update - March 2013
Advocacy Update - October 2013
Advocacy Update - September 2012
Advocacy Update: The Healthcare Landscape in the Aftermath of the 2012 Elections
As the Bill Turns...Episode 3
ASCO 2012: Dr. Pashos - Race- and health-related quality of life among patients newly diagnosed with multiple myeloma
ASCO 2013: Dr. Jakubowiak - Treatment outcome with the combination of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) for newly diagnosed multiple myeloma (NDMM) after extended follow-up.
ASCO 2013: Dr. Lonial - Phase (Ph) I/II study of elotuzumab (Elo) plus lenalidomide/dexamethasone (Len/dex) in relapsed/refractory multiple myeloma (RR MM): Updated Ph II results and Ph I/II long-term safety.
ASCO 2013: Dr. Pandey - Beneficial effect of complete response and type of therapy in multiple myeloma.
ASCO 2013: Dr. Usmani - Retrospective analysis of cardiovascular (CV) events following compassionate use of carfilzomib (CFZ) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM).
ASCO 2013: Dr. Weisel - MM-003: A phase III, multicenter, randomized, open-label study of pomalidomide (POM) plus low-dose dexamethasone (LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM).
ASH 2012: A PREVIEW
ASH 2013: Dr. Ken Anderson's Overview
Audio Recording of Consensus on Care: Management of Side Effects of Novel Therapies Teleconference
August 2013 Advocate of the Month: Judy Lewis
Breaking News: Pomalyst® (pomalidomide) Approved by the FDA for Relapsed Myeloma
FDA Recognition of Extended Survival with VELCADE® Indicates Important New Progress in Treating the Disease
Health Reform and You: The ABC’s of the ACA for Private Health Insurance
IMF 6th Annual Comedy Celebration
benefiting the Peter Boyle Research Fund
October 27, 2012
IMF Board Member Edith Mitchell, M.D., FACP, Named 2012 Recipient Of ASCO Humanitarian Award
IMF Nurse Leadership Board (NLB) White Paper on Subcutaneous Velcade® (bortezomib)
IMF Responds to Proposed Changes in CMS PET Scan Policy
It is Officially Myeloma Awareness Month Across the Country!
jc test
Live from ASH 2012: Journalists’ Workshop with Leading Myeloma Experts
Live! The Boca Raton Patient & Family Seminar
Living Well with Myeloma Teleconference Series:
How to Prevent Infection in Myeloma Patients
Myelom Merkur - Frühjahr 2012 - #901
MYELOMA AWARENESS MONTH 2012 FACT-A-DAY
Myeloma Canada Announces Recipient of this Year’s Research Grant
Myeloma Minute
April 11, 2013
Myeloma Minute
April 18, 2013
Myeloma Minute
April 26, 2012
Myeloma Minute
February 7, 2013
Myeloma Minute
January 31, 2013
Myeloma Minute
July 26, 2012
Myeloma Minute
June 28, 2012
Myeloma Minute
March 7, 2013
Myeloma Minute
May 17, 2012
Myeloma Minute
November 8, 2012
Myeloma Minute
October 24, 2013
Myeloma Minute
October 25, 2012
Myeloma Minute
May 24, 2012
Myeloma Today Spring 2013
New! Free Teleconference: Myeloma Updates 2012
Post ASCO/EHA/IMWG Summit
Patienten Handbuch
Pomalidomide + carfilzomib trial recruiting patients.
Should Myeloma Patients Get a Flu Shot? If So, Which One?
Special Myeloma Minute on FDA Approved Data for VELCADE®, including long-term survival data
STEP 7: CONSOLIDATION AND MAINTENANCE - ARE THEY NEEDED? REFERENCES
STEP 8: KEEPING TRACK OF THE MYELOMA - MONITORING WITHOUT MYSTERY
Stillwater, Minn., Myeloma Support Group Marks "Centennial" Anniversary
Teleconference: Myeloma Updates 2012
Post ASCO/EHA/IMWG Summit
The Emerging Role of Kyprolis in the Treatment Paradigm
The Hope Society
THE IMF AT ASH 2012
The IMF Spearheads New Coalition’s First Meeting on State Health Exchanges
The Importance of Clinical Trial Participation - A teleconference with Dr. Brian G. M. Durie
September 8,2011
The International Myeloma Foundation announces partnership with Onyx Pharmaceuticals to support Black Swan Research Initiative®
The International Myeloma Foundation Reports Live from the 2013 ASH Meeting in New Orleans
The International Myeloma Foundation to Convene First Global Leaders Summit in Stockholm to Raise Disease Awareness and Increase Access to Life-Saving Treatments
View the IMF’s Multiple Myeloma Journalists’ Workshop and Webcast from ASH 2013 in New Orleans
Webcast from the 2014 Boca Raton Patient & Family Seminar
February 28 - March 1, 2014

Клиническое значение электрофореза белковых фракций